545 related articles for article (PubMed ID: 30500439)
1. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
Ruark J; Mullane E; Cleary N; Cordeiro A; Bezerra ED; Wu V; Voutsinas J; Shaw BE; Flynn KE; Lee SJ; Turtle CJ; Maloney DG; Fann JR; Bar M
Biol Blood Marrow Transplant; 2020 Jan; 26(1):34-43. PubMed ID: 31605820
[TBL] [Abstract][Full Text] [Related]
4. Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study).
Hughes SE; McMullan C; Aiyegbusi OL; Shaw K; Kinsella F; Ferguson P; Khatsuria F; Burns D; Pyatt L; Ansell J; Chakera E; Richardson-Abraham J; Denniston AK; Davies EH; Craddock C; Calvert M
BMJ Open; 2024 Mar; 14(3):e085392. PubMed ID: 38553074
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
[TBL] [Abstract][Full Text] [Related]
6. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.
Sidana S; Dueck AC; Thanarajasingam G; Griffin JM; Thompson C; Durani U; Burtis M; Warsame R; Paludo J; Gertz MA; Dispenzieri A; Ansell SM; Rajkumar SV; Yost K; Bennani N; Lin Y; Kumar S
Transplant Cell Ther; 2022 Aug; 28(8):473-482. PubMed ID: 35550440
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
12. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
Tschernia NP; Heiling H; Deal AM; Cheng C; Babinec C; Gonzalez M; Morrison JK; Dittus C; Dotti G; Beaven AW; Serody JS; Wood WA; Savoldo B; Grover NS
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37527906
[TBL] [Abstract][Full Text] [Related]
14. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
15. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
16. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
17. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Oluwole OO; Dholaria B; Knight TE; Jain T; Locke FL; Ramsdell L; Nikiforow S; Hashmi H; Mooney K; Bhaskar ST; Morris K; Gatwood K; Baer B; Anderson LD; Hamadani M
Transplant Cell Ther; 2024 Feb; 30(2):131-142. PubMed ID: 37951502
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Kamal M; Joseph J; Greenbaum U; Hicklen R; Kebriaei P; Srour SA; Wang XS
Transplant Cell Ther; 2021 May; 27(5):390.e1-390.e7. PubMed ID: 33965176
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]